4D Molecular Corp (FDMT) - צמיחת רווח נקי למניה השנה

4D Molecular Therapeutics (FDMT) relies on external partners for vector production and testing. The company's innovations are based on creating unique viruses for targeted drug delivery, however, the absence of commercial products leads to capital expenditure on R&D. This chart on GURU.Markets reflects the current YoY EPS change, where the level of -73.30 is the current value, exposing imbalances in the market valuation.
פילוחי נתונים אנליטיים מרוכזים עבור 4DMT (FDMT)

The success of 4D Molecular Therapeutics (FDMT) is driven by the results of gene therapy clinical trials, rendering the business independent of economic cycles and seasonality. The year-over-year earnings per share trend reflects the efficiency of capitalizing on these developments, allowing investors to assess the growth rate of the asset's real return through an analysis of EPS YoY changes.